Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

36
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
36
Behavior Therapy01:22

Behavior Therapy

47
Behavior therapy incorporates diverse techniques rooted in classical conditioning principles to address maladaptive behaviors and anxiety disorders. These methods aim to reduce avoidance behaviors, foster adaptive coping mechanisms, and alter associations between stimuli and responses, making them effective in a wide range of therapeutic contexts.
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
47
Modeling in Therapy01:26

Modeling in Therapy

70
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
70
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

370
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
370
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

225
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
225
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

114
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
114

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Androgenetic Alopecia: Narrative Review of Current Therapies and Proposal of a Practical Algorithm for Pharmacological Treatment.

Actas dermo-sifiliograficas·2026
Same author

Characterization of Necrosis in the Recipient Area After Hair Transplantation: Multicenter Retrospective Study of 52 Patients.

Actas dermo-sifiliograficas·2026
Same author

Persistent Chemotherapy-Induced Alopecia: Updates in Diagnosis and Treatment Persistent Chemotherapy Induced Alopecia: An Updated Approach.

Actas dermo-sifiliograficas·2026
Same author

FUE for the repair of unnaturally designed or low hairlines in men with androgenetic alopecia: a retrospective, multicenter observational study.

Frontiers in medicine·2026
Same author

Post-Finasteride Syndrome: Survey of Dermatologists From the Spanish Hair and Nail Disorders Group.

Actas dermo-sifiliograficas·2026
Same author

Prescribing Habits for Androgenetic Alopecia Among Dermatologists in Spain in 2024: A Cross-Sectional Study.

Actas dermo-sifiliograficas·2026

Related Experiment Video

Updated: Jun 25, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K

Trichotillomania Treatment Update.

L Nina Dominguez1, A Imbernón-Moya2, D Saceda-Corralo3

  • 1Servicio de Dermatología, Instituto Dermatológico Dominicano y Cirugía de Piel «Dr. Huberto Bogaert Díaz», Santo Domingo, República Dominicana.

Actas Dermo-Sifiliograficas
|May 20, 2024
PubMed
Summary

Trichotillomania (TTM) is a hair-pulling disorder. N-acetylcysteine and memantine show promise as first-line treatments, offering a favorable safety and efficacy profile for managing TTM.

Keywords:
AlopeciaCognitive behavioral therapyObsessive-compulsive disorderPsicofármacosPsicoterapiaPsychotherapyPsychotropic drugsTerapia cognitivo conductualTrastorno obsesivo compulsivo

More Related Videos

How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression
07:00

How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression

Published on: January 23, 2017

24.1K
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

22.3K

Related Experiment Videos

Last Updated: Jun 25, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K
How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression
07:00

How to Use the H1 Deep Transcranial Magnetic Stimulation Coil for Conditions Other than Depression

Published on: January 23, 2017

24.1K
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

22.3K

Area of Science:

  • Dermatology
  • Psychiatry
  • Pharmacology

Background:

  • Trichotillomania (TTM) is an obsessive-compulsive disorder characterized by recurrent hair pulling, leading to alopecia.
  • Managing TTM presents a therapeutic challenge, requiring diverse treatment approaches.

Purpose of the Study:

  • To review current treatment modalities for Trichotillomania.
  • To highlight effective pharmacological and non-pharmacological interventions.

Main Methods:

  • Literature review of existing studies on TTM management.
  • Analysis of pharmacological and non-pharmacological treatment options.

Main Results:

  • Cognitive-behavioral therapy is a successful non-pharmacological option, though not universally adopted.
  • N-acetylcysteine and memantine are recommended first-line therapies due to their safety and efficacy.
  • Other medications like fluoxetine, clomipramine, olanzapine, and naltrexone have limited evidence of efficacy.

Conclusions:

  • Current TTM management involves a combination of therapies.
  • N-acetylcysteine and memantine represent promising first-line treatments for TTM.
  • Further research may explore unconventional tools like electronic devices and microneedling.